
Topic
Generic Entry
ANDA approvals, authorized generics, generic launch sequencing, patent expiry, and formulary shifts after generic entry.

Generics· June 24, 2026 · 17 min read
By Ran Chen#Generics#Generic Entry#Drug Pricing

Generics· June 24, 2026 · 18 min read
When is Generic Imbruvica Available? The 522-Patent Wall and Litigation Settlement Reality
By Ran Chen#Orange Book#Generics#Generic Entry

Generics· June 23, 2026 · 17 min read
Eliquis Generic: Why US Entry is Delayed to April 2028 Despite IRA Cuts
By Ran Chen#Generic Entry#FDA Approval#Orange Book

Generics· June 23, 2026 · 17 min read
When is Generic Ozempic Available? The US Semaglutide Patent-Cliff Reality
By Ran Chen#Generic Entry#FDA Approval#Orange Book

Generics· June 21, 2026 · 7 min read
Generic Liraglutide ANDAs: The Orange Book AP1 vs. AP2 Split
By Ran Chen#Generic Entry#FDA Approval#Market Access

Policy· June 21, 2026 · 7 min read
Sitagliptin's May 2026 Generic Launch and Januvia's IRA MFP Termination

Generics· June 20, 2026 · 10 min read
Discontinued RLDs and Reference Standards: Generic Developer Workflow
By Ran Chen#Orange Book#ANDA Approval#Generic Entry

Generics· June 16, 2026 · 12 min read
Single-source transdermal patches in the Orange Book: 385 products, 43% no generic
By Ran Chen#Orange Book#ANDA Approval#Generic Entry

Generics· June 14, 2026 · 10 min read
Single-source inhaled drugs in the Orange Book: 506 products, 65% no generic
By Ran Chen#Orange Book#ANDA Approval#Generic Entry

Generics· June 14, 2026 · 11 min read
Single-source ophthalmic drops in the Orange Book: 67 molecules, 11% AB-substitutable
By Ran Chen#Orange Book#ANDA Approval#Generic Entry